morepen laboratories has accepted the resignation of Mr. Bhola Prasad from the position of General Manager – Process Engineering & Technology Transfer, effective July 6, 2026. The company disclosed that the resignation was submitted due to personal reasons and the employee's intention to explore career growth outside the organization. Mr. Bhola Prasad was a functional head and classified as a Senior Management Personnel.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing referenced the SEBI master circular regarding the disclosure of changes in senior management personnel. The resignation was submitted with immediate effect, and Mr. Bhola Prasad expressed his intention to ensure a smooth handover of responsibilities.

Details of Resignation

The following table outlines the particulars of the change in senior management personnel as disclosed in the regulatory filing:

The resignation letter addressed to The AVP – Operations (API) at Morepen Laboratories Ltd. in Baddi formally requested relief from the position of GM Tech transfer & process Engineering. Mr. Bhola Prasad acknowledged the opportunities received during his tenure and committed to assisting in the transition process.

Morepen Laboratories Limited has commenced commercial supplies under its ₹825 crore contract development and manufacturing organization (CDMO) mandate, marking a transition from validation to full-scale execution. The company completed its first dispatch, valued at approximately ₹50 crore, during Q1FY2026-27. This milestone supports Morepen's strategy to build a scalable CDMO platform and deepen customer partnerships in long-duration global manufacturing opportunities.

Managing Director's Statement

Sanjay Suri, Managing Director of Morepen Laboratories, stated that the teams have worked closely with the customer through validation, manufacturing readiness, and supply-chain planning. The focus now shifts to scaling up operations, expanding capacity, and pursuing additional customer and product opportunities within the CDMO segment.

Supply Schedule and Projections

Following the initial dispatch, Morepen expects to accelerate the program in the coming quarter. The company projects additional supplies of approximately ₹225 crore during Q2FY2026-27, contingent upon customer schedules and regulatory or commercial requirements. The table below outlines the supply schedule under the mandate:

Manufacturing Infrastructure Expansion

To support larger CDMO opportunities, Morepen Laboratories is strengthening its manufacturing infrastructure. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, with subsequent phases targeting expansion toward 800 KL and 1,000 KL. The commencement of commercial supplies under this mandate reinforces Morepen's objective to participate in global manufacturing opportunities across APIs, finished formulations, diagnostics, and consumer healthcare.